For the quantification of estrone-3-glucuronide in biological matrices
Features
  • Measures estrone-3-glucuronide, the predominant metabolite of estradiol in biological matrices
  • Assay 24 samples in triplicate or 36 samples in duplicate
  • Lower limit of detection (LLOD) is 6.6 pg/ml
  • Rapid 2-hour or overnight incubation options
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Estrone-3-Glucuronide ELISA Kit

Item No. 501290

Kit Booklet (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Synonyms
  • E1G
  • Estrone Glucuronide
  • Estrone β-D-Glucuronide
  • Estrone-3-Glucuronide EIA Kit
Limit of Detection
6.6 pg/ml (overnight); 10.1 pg/ml (rapid)
Assay Range
2.7-6,000 pg/ml
Sensitivity
23.2 pg/ml (overnight); 36.1 pg/ml (rapid)
Cross Reactivity
(100%) Estrone-3-Glucuronide(133%) Estrone Sulfate(66%) Estrone(0.13%) Estradiol(0.1%) Estradiol Sulfate(0.008%) Progesterone(0.004%) Estriol(0.0004%) DHEA Sulfate(<0.01%) Estriol Glucuronide(<0.01%) Testosterone Glucuronide(<0.01%) Estradiol Glucuronide(<0.01%) Pregnanediol Glucuronide
Origin
Animal/Bovine, Animal/Rabbit
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    96 solid plate

    $315

    Add

    96 strip plate

    $315

    Add
    Bioanalysis & Assay Development Services
    Your Vision. Our Expertise.
    • Bioanalysis and compound screening using Cayman or qualified commercial assay kits
    • Development and qualification of fit-for-purpose assays in a variety of formats and platforms
    • Experienced scientists dedicated to developing the best strategy for your project
    LEARN MORE
    Product Description

    Estrone-3-glucuronide is the predominant metabolite of estradiol in urine and a urinary marker for the fertile window in women.1 Measurement of urinary glucuronides is a convenient, non-invasive method for detecting reproductive hormone levels compared to measuring plasma levels.2 Estrone-3-glucuronide, along with pregnanediol-3-glucuronide, are indicators of female reproductive health.2

    Literature has shown high serum estrone levels, which directly correlate to urinary estrone-3-glucuronide levels, are associated with estrogen receptor-positive breast cancers.3 Hormone receptor status is the main factor in planning treatment and can be treated with hormone therapies, including tamoxifen and aromatase inhibitors.4 In addition to its role in breast cancer, circulating estrogens, including estrone metabolized from oral hormone replacement therapy, have been shown to increase thrombin generation leading to higher risk for blood clots, myocardial infarctions, deep vein thrombosis and strokes.5,6

    Needed but not supplied: Please download the kit booklet to verify if UltraPure Water (Milli-Q or equivalent) or any other components are needed for this assay.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Eichner, S.F., and Timpe, E.M. Urinary-based ovulation and pregnancy: Point-of-care testing. Ann. Pharmacother. 38(2), 325-331 (2004).

    2. O'Connor, K.A., Brindle, E., Holman, D.J., et al. Urinary estrone conjugate and pregnanediol 3-glucuronide enzyme immunoassays for population research. Clin. Chem. 49(7), 1139-1148 (2003).

    3. Miyoshi, Y., Tanji, Y., Taguchi, T., et al. Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women. Clin. Cancer Res. 9(6), 2229-2233 (2003).

    4. Bagot, C.N., Marsh, M.S., Whitehead, M.I., et al. The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapyexa. J. Thromb. Haemost. 8(8), 1736-1744 (2010).

    5. Karim, R.M., Mack, W.J., Hodis, H.N., et al. Influence of age and obesity on serum estradiol, estrone, and sex hormone binding globulin concentrations following oral estrogen administration in postmenopausal women. J. Clin. Endocrinol. Metab. 94(11), 4136-4143 (2009).

    6. Dong, M., Mu, N., Ren, F., et al. Prospective study of effects of endogenous estrogens on myocardial no-reflow risk in postmenopausal women with acute myocardial infarction. J. Interv. Cardiol. 27(5), 437-443 (2014).